Feed INSM
IN

Insmed INSM · NASDAQ

$95.29 -1.02% (-$0.98)

Market cap
$20.8B
Enterprise value
$20.8B
P/E
-
Forward P/E
-
PEG
-
P/S
18.3x
P/FCF
-
EV/EBITDA
-
ROIC
-49.2%
Gross margin
83.3%
Net margin
-76.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.82
Free float
98.5%

About the company

Insmed Incorporated is an American biotechnology company focused on the development and commercialization of innovative therapies for patients suffering from rare and serious diseases. The company specializes in the treatment of lung diseases, particularly pulmonary hypertension and rare pulmonary infections, using advanced biologic and pharmaceutical products. Insmed is known for its work to improve the quality of life for patients who have no effective treatment options and focuses on developing new drugs for diseases that remain insufficiently treated.

Sector

Healthcare

Industry

Biotechnology

CEO

William H. Lewis

Employees

1,664

Headquarters

Bridgewater

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.